Finley John David sold $303K of PALI

Palisade Bio Inc. (PALI) dosed the first patient in its Phase 2b ASCENTRA-UC trial for ulcerative colitis, evaluating PALI-2108. The trial aims to enroll 204 patients and has 29 U.S. sites active, with global expansion ongoing. Topline results are expected in Q4 2027. PALI-2108 is an investigational oral PDE4 inhibitor prodrug. The company also conducts a Phase 2 study for Crohn’s disease.

Palisade Bio (PALI) dosed the first patient in its Phase 2b ASCENTRA-UC trial for ulcerative colitis, with topline results expected in Q4 2027. The trial plans to enroll ~204 patients and test the oral drug PALI-2108. A positive result would be a significant catalyst for the company, according to the company.

Oppenheimer reiterated an Outperform rating and $8.00 price target on Palisade Bio (NASDAQ:PALI) after additional data from UEG Week. The stock is down 49% over six months but has a Strong Buy consensus and targets ranging from $5 to $25. New tissue analyses showed reduced PDE4D expression and signs of tissue remodeling. Phase 2 trials are ongoing, with data expected in 2H27. Other analysts also reiterated or initiated positive ratings.

Palisade Bio (PALI) shares rose 9% after presenting early clinical data for PALI-2108, showing improvements in Crohn's disease patients. The Phase 1b study reported a 47.5% decrease in disease activity and 58.8% reduction in inflammation marker. The company is conducting further Phase 2 trials. PALI stock is currently at $1.46, up from its 52-week range of $1.32-$2.86.

Palisade Bio (NASDAQ:PALI) reported early-stage trial results for PALI-2108, showing reductions in Crohn's disease activity measures in a small, 5-patient study. The drug demonstrated decreases in disease scores and inflammation markers, with mild adverse events. The company is advancing to Phase 2 studies. Results are preliminary and require further validation.

Palisade Bio (PALI) reported early Phase 1b data for PALI-2108, showing reductions in endoscopic activity and fecal calprotectin in Crohn's patients. Phase 2b UC trial is enrolling, and a Phase 2a Crohn's study is starting. The company noted these are early, open-label results.